Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Inclusion Criteria: * Patients with a histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or epithelial fallopian tube carcinoma * Patients with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, transitional cell carcinoma, and mixed epithelial carcinoma * Patients with advanced stage refractory ovarian carcinoma: patients unable to achieve first complete remission (CR) with first or second line chemotherapy OR patients with disease relapse after achieving second CR * Patients must be 30 days out from last chemotherapy; previous chemotherapy must include a platinumbased regimen and paclitaxel (Taxol) * Patients must have undergone primary debulking surgery * Patients must have a peritoneal catheter suitable for I.P. infusion * White blood cell count (WBC) \> 3.0 THOU/ul * Serum creatinine =\< 2.5 mg/dL * ALT =\< 2.5 x upper limit of normal * AST =\< 2.5 x upper limit of normal * Total bilirubin =\< 2.0 x upper limit of normal * Albumin \>= 3.0 g/dL * Subjects must have a Performance Status Score (Zubrod/SWOG Scale) =\< 2 * Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment * Lymphocytes \> 1.0 THOU/ul * Platelets \>= 100 THOU/ul Exclusion Criteria: * Prior treatment with ONTAK (DAB389IL-2) or DAB486IL-2 * Known history of hypersensitivity to diphtheria toxin or IL-2 * Moderate (symptomatic requiring the use of diuretics) or severe (symptomatic requiring paracentesis or other invasive intervention) ascites * Active autoimmune disease * Known history of pulmonary disease except controlled asthma * Known history significant cardiac disease * Concurrent malignancy requiring active treatment * Clinical or radiological evidence of acute bowel obstruction within 30 days of enrollment